Tomahawk, WI 05/19/2014 (Basicsmedia) –Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) came up with a holistic review of the previous quarter on May 1, 2014. The company improved its percentage earning by a whopping margin of 30.1% in Q1-2014, year-over-year. However, over the last few months, VRTX had shown up a number of Hammer Chart Patterns owing to the highs and lows, marked by volatility in the net earnings!

Vertex Shares Volatile

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has also cited that its Return on Equity (or ROE) has increased significantly last quarter, in comparison to the same in Q1-2013. This shows significant, sustained strength and prowess of the company, however, its ROE is far too lesser than the Biotechnology industry average. Despite aggravating its EPS to $0.65, VRTX has plummeted down its revenues by 63.9% YoY, to a staggering $118.50 million, in Q1-2014; the net income, however, scaled up in Q1-2014 by a significant 24.5% YoY in Q1-2014.

VRTX that reigns in the realm of discovering, manufacturing and commercializing myriad drugs has reported a P/E ratio of 147.5. Moreover VRTX, one of the leading drug manufacturers catering to the Health Sector, possesses market capitalization of $15.36 billion. VRTX also denoted about Non-GAAP R&D expenses of $181.5 million in Q12014.

VRTX has a significant low of $58.06 per share over the past one year, and a 52-week high of thumping $89.96 per share. In last 50-days the stock’s averages is $66.57; whereas, its 200-Days average stands at $72.28 per share.

Losses And Promises

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) had notched up Non-GAAP revenues worth $108.2 million in Q1-2014. Key Net GAAP Loss stands at $232 million whereas the Non-GAAP loss amounted to $151 million. However, the company seems focused on marketing varied transformative medicines, innovative and diverse pipeline, and promises its investors of acquiring sustained revenues and solicit prudent earnings growth.

HQ Lease Out Until 2029

The last time when the VRTX stocks were faring very poorly, the Fallon Company chose to lease out its two-building headquarters in Boston to the SNH (Senior Housing Property Trust) through 2029, on December 2013.

Young On-Board

A great leader hailing from the Biotech Industry, Mr. William Young joined the Directorial Board of VRTX, which now comprises 10 members. Mr. Young’s expertise and knowhow would certainly bolster and improve Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s businesses and research in the regimen of transformative medicines in near future.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.